Statements of Cash Flows (USD $)	12 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Cash Flows from Operating Activities:
Net Income	$ 6,875,073	$ 3,309,019
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,230,250	2,073,006
Abandoned patents written off	76,231	79,958
Provision for bad debts	1,050,442	963,009
Compensatory element of stock issuances	180,418	204,486
Stock issued for costs and expenses	427,558	862,811
(Increase) decrease in operating assets, net:
Accounts, management fee and medical receivable(s)	(996,720)	(1,550,287)
Notes receivable	80,845	(336,717)
Costs and estimated earnings in excess of Billings on uncompleted contracts	(959,153)	107,941
Inventories	205,291	425,971
Prepaid expenses and other current assets	177,593	200,894
Other assets	108,054	(57,724)
Advances and notes to related medical practices		83,423
Increase (decrease) in operating liabilities, net:
Accounts payable	(164,669)	(1,012,493)
Other current liabilities	(830,644)	699,929
Customer advances	(964,510)	32,467
Billings in excess of costs and estimated earnings on uncompleted contracts	(4,045)	(2,739,353)
Other liabilities	(101,304)	27,255
Due to related medical practices	474	(299,624)
Income tax payable	25,000	75,000
NET CASH PROVIDED BY OPERATING ACTIVITIES	7,416,184	3,148,971
Cash Flows from Investing Activities:
Sales of marketable securities	(2,839)	(2,608)
Purchases of property and equipment	(1,081,209)	(532,562)
Costs of capitalized software development		(67,258)
Cash acquired from business combination		290,102
Cost of patents	(146,163)	(135,210)
NET CASH USED IN INVESTING ACTIVITIES	(1,230,211)	(447,536)
Cash Flows from Financing Activities
Proceeds from non controlling interest		6,700,000
Proceeds from debt	246,000
Repayment of borrowings and capital lease obligations	(1,387,225)	(1,492,546)
Repayment of notes receivable from employee stockholders	44,492	75,862
Distributions to non controlling interests	(1,135,000)	(22,500)
Redemption of Non-Controling Interests	(1,200,000)
Purchase of Non Controling Interest		(10,500)
Proceeds from Non Controlling Interest	16,031
Sale to non controlling interest	10,500
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(3,405,202)	5,250,316
Net Increase in Cash and Cash Equivalents	2,780,771	7,951,751
Cash and Cash Equivalents Beginning of Year	9,251,244	1,299,493
Cash and Cash Equivalents - End of Year	$ 12,032,015	$ 9,251,244